Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics (Q27851412)

PubMed

PubMed publication ID

17891190

13 November 2016

title

Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics (English)

1 reference

publication type of scholarly work

PubMed

PubMed publication ID

13 November 2016

1 reference

1 reference

2

Dolors Colomer

0 references

Pedro Jares

object named as

Pedro Jares

series ordinal

1

0 references

Elías Campo

object named as

Elias Campo

series ordinal

3

0 references

publication date

October 2007

0 references

language of work or name

English

0 references

published in

Nature Reviews Cancer

0 references

volume

7

0 references

issue

10

0 references

page(s)

750-62

0 references

review article

1 reference

Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes

Europe PubMed Central

cites work

1 reference

Clonal proliferation of cyclin D1-positive mantle lymphocytes in an asymptomatic patient: an early-stage event in the development or an indolent form of a mantle cell lymphoma?

31 March 2020

1 reference

A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease

31 March 2020

1 reference

Mechanisms of B-cell lymphoma pathogenesis

31 March 2020

1 reference

The impact of translocations and gene fusions on cancer causation

31 March 2020

1 reference

Spatial proximity of translocation-prone gene loci in human lymphomas

31 March 2020

1 reference

Alkaline Phosphatase-positive Malignant Lymphoma: A Subtype of B-cell Lymphomas

31 March 2020

1 reference

Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data

31 March 2020

1 reference

31 March 2020

1 reference

Molecular heterogeneity in MCL defined by the use of specific VH genes and the frequency of somatic mutations.

31 March 2020

1 reference

VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome

31 March 2020

1 reference

ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

31 March 2020

1 reference

Immunohistochemical analysis of ZAP-70 expression in B-cell lymphoid neoplasms

31 March 2020

1 reference

Molecular diagnosis of t(11;14) in mantle cell lymphoma using two-colour interphase fluorescence in situ hybridization

31 March 2020

1 reference

Visualization of mono-allelic chromosomal aberrations 3′ and 5′ of the cyclin D1 gene in mantle cell lymphoma using DNA fiber fluorescence in situ hybridization

31 March 2020

1 reference

Point mutations and genomic deletions in CCND1 create stable truncated cyclin D1 mRNAs that are associated with increased proliferation rate and shorter survival

31 March 2020

1 reference

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

31 March 2020

1 reference

Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1.

31 March 2020

1 reference

Cyclin D1/PRAD1/BCL-1 alternative transcript [B] protein product in B-lymphoid malignancies with t(11;14)(q13;q32) translocation

31 March 2020

1 reference

Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation

31 March 2020

1 reference

Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization

31 March 2020

1 reference

Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation

31 March 2020

1 reference

Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age

31 March 2020

1 reference

Functional interactions of the retinoblastoma protein with mammalian D-type cyclins

31 March 2020

1 reference

Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis.

31 March 2020

1 reference

Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis

31 March 2020

1 reference

Expression of the cyclin-dependent kinase inhibitor p27 and its deregulation in mouse B cell lymphomas

31 March 2020

1 reference

Minireview: Cyclin D1: normal and abnormal functions

31 March 2020

1 reference

Linking cyclins to transcriptional control.

31 March 2020

1 reference

Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling

31 March 2020

1 reference

Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature

31 March 2020

1 reference

A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus

31 March 2020

1 reference

Function of a human cyclin gene as an oncogene

31 March 2020

1 reference

Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice.

31 March 2020

1 reference

Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma

31 March 2020

1 reference

Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity.

31 March 2020

1 reference

Relevance of cyclin D1b expression and CCND1 polymorphism in the pathogenesis of multiple myeloma and mantle cell lymphoma

31 March 2020

1 reference

Low prevalence of circulating t(11;14)(q13;q32)-positive cells in the peripheral blood of healthy individuals as detected by real-time quantitative PCR.

31 March 2020

1 reference

t(11;14)-positive mantle cell lymphomas exhibit complex karyotypes and share similarities with B-cell chronic lymphocytic leukemia

31 March 2020

1 reference

Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization

31 March 2020

1 reference

Genomic DNA-chip hybridization in t(11;14)-positive mantle cell lymphomas shows a high frequency of aberrations and allows a refined characterization of consensus regions

31 March 2020

1 reference

Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome

31 March 2020

1 reference

Novel chromosomal imbalances in mantle cell lymphoma detected by genome-wide array-based comparative genomic hybridization

31 March 2020

1 reference

Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM.

31 March 2020

1 reference

Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

31 March 2020

1 reference

Blastic mantle cell lymphoma associated with Burkitt‐type translocation and hypodiploidy

31 March 2020

1 reference

Partial uniparental disomy: a recurrent genetic mechanism alternative to chromosomal deletion in malignant lymphoma

31 March 2020

1 reference

Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias

31 March 2020

1 reference

Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines

31 March 2020

1 reference

Mantle cell lymphoma-derived cell lines: unique research tools

31 March 2020

1 reference

Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways

31 March 2020

1 reference

The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status

31 March 2020

1 reference

The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak

31 March 2020

1 reference

Molecular cytogenetic characterization of the mantle cell lymphoma cell line GRANTA-519.

31 March 2020

1 reference

Differential effect of epigenetic alterations and genomic deletions of CDK inhibitors [p16(INK4a), p15(INK4b), p14(ARF)] in mantle cell lymphoma

31 March 2020

1 reference

The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus

31 March 2020

1 reference

CDK4andMDM2Gene Alterations Mainly Occur in Highly Proliferative and Aggressive Mantle Cell Lymphomas with Wild-typeINK4a/ARFLocus

31 March 2020

1 reference

Increased MDM2 expression is associated with inferior survival in mantle cell lymphoma, but not related to the MDM2 SNP309

31 March 2020

1 reference

31 March 2020

1 reference

Mantle cell lymphoma is characterized by inactivation of the ATM gene

31 March 2020

1 reference

ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances

31 March 2020

1 reference

Oligonucleotide microarrays demonstrate the highest frequency of ATM mutations in the mantle cell subtype of lymphoma

31 March 2020

1 reference

ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma

31 March 2020

1 reference

Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias

31 March 2020

1 reference

Mechanisms of chromosomal translocations in B cell lymphomas

31 March 2020

1 reference

The DNA damage response: putting checkpoints in perspective

31 March 2020

1 reference

CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas

31 March 2020

1 reference

Mutations of Chk2 in primary hematopoietic neoplasms

31 March 2020

1 reference

Checkpoint kinase 1 (CHK1) protein and mRNA expression is downregulated in aggressive variants of human lymphoid neoplasms

31 March 2020

1 reference

Unbalanced expression of licensing DNA replication factors occurs in a subset of mantle cell lymphomas with genomic instability

31 March 2020

1 reference

Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis

31 March 2020

1 reference

Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma

31 March 2020

1 reference

Selective Inhibition of I B Kinase Sensitizes Mantle Cell Lymphoma B Cells to TRAIL by Decreasing Cellular FLIP Level

31 March 2020

1 reference

Treatment of mantle cell lymphoma: current approach and future directions

31 March 2020

1 reference

Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis

31 March 2020

1 reference

Current treatment approaches for mantle-cell lymphoma

31 March 2020

1 reference

Targeting histones and proteasomes: new strategies for the treatment of lymphoma

31 March 2020

1 reference

Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy

31 March 2020

1 reference

Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma

31 March 2020

1 reference

In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.

31 March 2020

1 reference

Evaluation of novel cell cycle inhibitors in mantle cell lymphoma

31 March 2020

1 reference

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

31 March 2020

1 reference

Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma

31 March 2020

1 reference

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

31 March 2020

1 reference

Apoptosis-based therapies for hematologic malignancies

31 March 2020

1 reference

The Bcl-2 apoptotic switch in cancer development and therapy

31 March 2020

1 reference

MCL-1 expression in B-cell non-Hodgkin's lymphomas

31 March 2020

1 reference

Expression of Mcl-1 in mantle cell lymphoma is associated with high-grade morphology, a high proliferative state, and p53 overexpression

31 March 2020

1 reference

Comparison of chemical inhibitors of antiapoptotic Bcl-2-family proteins

31 March 2020

1 reference

Targeting death receptors in cancer with Apo2L/TRAIL.

31 March 2020

1 reference

TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies

31 March 2020

1 reference

Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma

31 March 2020

1 reference

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

31 March 2020

1 reference

Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma

31 March 2020

1 reference

Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma

31 March 2020

1 reference

Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies

31 March 2020

1 reference

Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines

31 March 2020

1 reference

HDACs, histone deacetylation and gene transcription: from molecular biology to cancer therapeutics

31 March 2020

1 reference

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

31 March 2020

1 reference

Thalidomide therapy induces response in relapsed mantle cell lymphoma

31 March 2020

1 reference

Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma

31 March 2020

1 reference

Nuclear survivin expression in mantle cell lymphoma is associated with cell proliferation and survival

31 March 2020

1 reference

The heat shock protein 90 inhibitor 17-AAG induces cell cycle arrest and apoptosis in mantle cell lymphoma cell lines by depleting cyclin D1, Akt, Bid and activating caspase 9.

31 March 2020

1 reference

Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors

31 March 2020

1 reference

Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network

31 March 2020

1 reference

Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes

31 March 2020

1 reference